2008 Healthcare Conference Still using a ruler to project the future? Sameet Shah FIA, Marketing Actuary Pierre Coetzee FIA, Securitisation Transaction.

Slides:



Advertisements
Similar presentations
Andrew D Smith April 2005 Stochastic Mortality Andrew D Smith April 2005 Deloitte.
Advertisements

Agency for Healthcare Research and Quality (AHRQ)
Insurance Premium Risk, Competition and the Insurance Cycle George Maher.
Course on Professionalism ASOP 43 – Property / Casualty Unpaid Claim Estimates.
What does integrated statistical and contextual knowledge look like for 3.10? Anne Patel & Jake Wills Otahuhu College & Westlake Boys High School CensusAtSchool.
Prepared for D ISABILITY C LAIMS R I S I N G Adrian C T Mak GeneralCologne Life Re Australia.
Estimating Direct Effects of New HIV Prevention Methods. Focus: the MIRA Trial UCSF: Helen Cheng, Nancy Padian, Steve Shiboski, Ariane van der Straten.
Tim Rozar FSA, MAAA, CERA Derek Kueker FSA Lapse and Mortality of Post-Level Period Term Plans International Actuarial Association.
Wisconsin HIV/AIDS Surveillance Annual Review: Slide Set New diagnoses, prevalent cases, and deaths through December 2014 April 2015 P Wisconsin.
Critical Illness – Lessons to Learn from UK Market 10 th Global Conference of Actuaries 7-8 th February 2008 Mumbai, India SUNIL SHARMA, MSc, FIA, FASI.
Service Users subject to s. 41 of the Mental Health Act Their views of risk and risk assessments Jeremy Dixon.
Ab Financial Incentives in Life Insurance (Preferred risk products) 16th European Congress on Obesity Geneva, Switzerland May 16, 2008 Dieter Gaubatz,
Measures of disease frequency (I). MEASURES OF DISEASE FREQUENCY Absolute measures of disease frequency: –Incidence –Prevalence –Odds Measures of association:
Cohort Studies Hanna E. Bloomfield, MD, MPH Professor of Medicine Associate Chief of Staff, Research Minneapolis VA Medical Center.
PROSTATE CANCER AND SMOKING Kym Hickey MBBS, MPH Repatriation Medical Authority, Australia.
The Nature of Disease.
Unit 1: Overview of HIV/AIDS Case Reporting #6-0-1.
Wisconsin Department of Health Services HIV/AIDS Surveillance Annual Review New diagnoses, prevalent cases, and deaths through December 31, 2013 April.
Measurement Measuring disease and death frequency FETP India.
Measuring disease and death frequency
New Zealand Society of Actuaries Financial Services Forum 27 November 2009.
Development of the UK longevity market Rajeev Shah 9 December 2009.
Chapter 8 Insurance Pricing.
FINANCIAL CONDITION REPORTING Ioana Abrahams 13 November 2009.
1 POPULATION PROJECTIONS Session 2 - Background & first steps Ben Jarabi Population Studies & Research Institute University of Nairobi.
GE Frankona Re g Valuing Healthcare - Introduction to Pricing Ash Desai.
Investigation into evidence for economies of scale in the water and sewerage industry in England and Wales Presentation of Findings Water UK City Conference,
Slide 1 Trend Sources and Techniques, A Comparison of US and European Methods Trending of Premium and Claims A Reinsurer’s Perspective FIT FOR PURPOSE.
CIA Annual Meeting Assemblée annuelle de l’ICA June 29 & 30, 2006  Les 29 et 30 juin 2006 Ottawa, Ontario Individual & Group Style Pricing.
 The 2003 Healthcare Conference Actuaries Adding Value 5-7 October 2003 Scarman House, The University of Warwick.
2009 Annual Meeting ● Assemblée annuelle 2009 Halifax, Nova Scotia ● Halifax (Nouvelle-Écosse) 2009 Annual Meeting ● Assemblée annuelle 2009 Halifax, Nova.
HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System HIV in the United Kingdom: 2012 Overview.
Methodology for producing the revised back series of population estimates for Julie Jefferies Population and Demography Division Office for.
The 3 rd Younger Members Convention November 2004, The Chesford Grange Hotel, Kenilworth.
Abcd 2001 Healthcare Conference Keeping Health on Track October 2001 Scarman House.
Workers’ Compensation Managed Care Pricing Considerations Prepared By: Brian Z. Brown, F.C.A.S., M.A.A.A. Lori E. Stoeberl, A.C.A.S., M.A.A.A. SESSION:
Epidemiology of HIV Among Men in Florida, Reported through 2012 Florida Department of Health HIV/AIDS and Hepatitis Section Division of Disease Control.
© 2007 Towers Perrin June 17, 2008 Loss Reserving: Performance Testing and the Control Cycle Casualty Actuarial Society Pierre Laurin.
Life expectancy of patients treated with ART in the UK: UK CHIC Study Margaret May University of Bristol, Department of Social Medicine, Bristol.
UK Aid Direct Introduction to Logframes (only required at proposal stage)
 The 2003 Healthcare Conference 5-7 October 2003 Scarman House, The University of Warwick.
Asbestos Valuation CLRS – Chicago; September 8, 2003 Kevin M. Madigan, PhD, ACAS, MAAA Vice President, Platinum Underwriters Bermuda, Ltd. Claus S. Metzner,
Ab Rate Monitoring Steven Petlick CAS Underwriting Cycle Seminar October 5, 2009.
Measures of Disease Frequency
 The 2002 Healthcare Conference Surviving or Thriving ? 29 September-1 October 2002 Scarman House, The University of Warwick, Coventry.
Improving Cancer Outcomes in Camden Dr Lucia Grun 19 March 2014.
Health insurance claims distributions Robert Cole NZ Society of Actuaries conference Nov 2010.
HOW ARE PRIORITY ISSUES FOR AUSTRALIA’S HEALTH IDENTIFIED? HEALTH PRIORITIES IN AUSTRALIA.
©Towers Perrin Introduction to Reinsurance Reserving Casualty Loss Reserve Seminar Atlanta, Georgia September 11, 2006 Christopher K. Bozman, FCAS, MAAA.
Developed from information included in the AIHW report Cancer in Australia: in brief 2014 Highlights.
Katarina Grande, HIV Surveillance Coordinator Casey Schumann, HIV Epidemiologist Wisconsin Department of Health Services Statewide Action Planning Group.
Setting NAPLAN DATA Targets Presented by Philip Holmes-Smith School Research Evaluation and Measurement Services.
Consultation on Guidance for (Re)Insurance undertakings on the Head of Actuarial Function Role (CP 103) Presentation to Society of Actuaries in Ireland.
Case Control study. An investigation that compares a group of people with a disease to a group of people without the disease. Used to identify and assess.
Impact of HIV Disease, Among the Caribbean-Born, Florida, 2014 Florida Department of Health HIV/AIDS Section Division of Disease Control and Health Protection.
Life Underwriting Challenges and Policyholder Behaviour 22 April 2016 André Basson Central Actuarial Services Hollard Group Organisation of Southern and.
CAS Ratemaking Seminar COM-21 Medical Malpractice Pricing Jeff Donaldson, FCAS, MAAA The Doctors’ Company.
Agenda Introduction Definition of non-disclosure
CISI – Financial Products, Markets & Services
Dementia Risk Reduction Melanie Earlam PHE 27th September 2016
Forecasting Methods Dr. T. T. Kachwala.
1 The roles of actuaries & general operating environment
The 2002 Healthcare Conference
Table 1: New HIV diagnoses, by UK country,
Direct Life Manager's Briefing
Kathleen England Neville Calleja 20th October 2017
Shepherd Fungura, BCom, FASSA, FIA
Pest Risk Analysis (PRA) Stage 2: Pest Risk Assessment
6 questions = 8% of the exam
Epidemiological Terms
Presentation transcript:

2008 Healthcare Conference Still using a ruler to project the future? Sameet Shah FIA, Marketing Actuary Pierre Coetzee FIA, Securitisation Transaction Manager 15 May 2008

Slide 2 Agenda Experience analysis – a brief overview Finding a plausible answer Risk selection CI related issues Changing HIV limits Impact of high lapses Quantifying impact of changes

Slide 3 Agenda Experience analysis – a brief overview Finding a plausible answer Risk selection CI related issues Changing HIV limits Impact of high lapses Quantifying impact of changes

Slide 4 Experience analysis – a brief overview “Making sense of the past” – Luc and Spivak Good quality data – Complete and correct capture of all risk factors – Be careful of different data cohorts causing heterogeneity Correct age definitions (4-8% impact) Using an appropriate table (by age, sex and smoker status) Applying appropriate IBNR factors (4% impact) Retain all factors in data, e.g. don’t lose product type split Roll data forward to allow for trends, e.g. rebase to current year

Slide 5 Agenda Experience analysis – a brief overview Finding a plausible answer Risk selection CI related issues Changing HIV limits Impact of high lapses Quantifying impact of changes

Slide 6 Finding a plausible answer Act/Exp eventsAct/Exp amounts

Slide 7 Finding a plausible answer All underwriting yearsRecent underwriting years Act/Exp eventsAct/Exp amounts

Slide 8 Agenda Experience analysis – a brief overview Finding a plausible answer Risk selection CI related issues Changing HIV limits Impact of high lapses Quantifying impact of changes

Risk selection % Accepted on Standard Rates 75% 80% 85% 90% 95% 100% Q1 Yr1Q3 Yr1Q1 Yr2Q3 Yr2Q1 Yr3Q3 Yr3Q1 Yr4 Q3 Yr4 Q1 Yr5Q3 Yr5Q1 Yr6Q3 Yr6Q1 Yr7Q3 Yr7Q1 Yr8Q3 Yr8 Higher non- medical limits Revised application form - longer! Tougher u/w criteria Regular u/w audits introduced Switch to tele u/w Brokers taking difficult cases somewhere else due to slow turnaround Turnaround times improve

Slide 10 Agenda Experience analysis – a brief overview Finding a plausible answer Risk selection CI related issues Changing HIV limits Impact of high lapses Quantifying impact of changes

Slide 11 CI related issues Impact of external factors Troponins No data adjustment could understate average experience over analysis period Care needs to be taken when measuring historical trend => could overstate future experience Cancer Screening Likely to cause “shock” in cancer incidence Dealing with shock will depend on its maturity or likelihood of occurring Calendar Year 1995 incidence rates rebased to 1 and 2 respectively Male heart attack incidence - relative to 1995 Impact of Troponins UK versus US prostate cancer incidence rates per 100, Age Incidence US 1986US 1992US 1998 UK 1986UK 1992UK 1998 Source: Hospital Episode Statistics data

Slide 12 CI related issues Product changes Adding new illnesses Starting point is HES data/internet, but number of adjustments are necessary Could often result in no cost, but need to be careful TCF issues? Experience unstable, trends unpredictable? Definitions tight as intended? Other unintended consequences? Age Age Calendar Year 1995 incidence rates rebased to 1 and 2 respectively Male multi-vessel angioplasty incidence - relative to 1995 Source: Hospital Episode Statistics data

Slide 13 Agenda Experience analysis – a brief overview Finding a plausible answer Risk selection CI related issues Changing HIV limits Impact of high lapses Quantifying impact of changes

Slide 14 Changing HIV limits Industry moves HIV medical limits for single males from £250K to up to £1M What’s the expected cost? New HIV diagnoses in the UK '97'98'99'00'01'02'03'04'05'06'07 MSM Heterosexual males Heterosexual females Source: Health Protection Agency

Slide 15 How could it be priced? QuestionPossible answer Anti-selective behaviourUnderwriting and claims management robust. Only identify lives aware they are HIV positive at issue. But no fishing allowed at claim stage! Estimated impact between 0.1% and 0.3% of portfolio claim cost Proportion of business from: – Single males with cover between £250k and £1m – Unaware they are HIV positive 10% 0.05% Assumed mortality rate for a life who is HIV positive Age specific mortality for HIV life based on Danish experience (equivalent to assuming life expectancy of 24 years for a male age 35) Assumed lapse behaviour once a life is aware that they are HIV positive Once life aware HIV positive then no lapses. Assume aware shortly after policy issue. Note that the later the diagnosis the higher the expected HIV mortality

Slide 16 Agenda Experience analysis – a brief overview Finding a plausible answer Risk selection CI related issues Changing HIV limits Impact of high lapses Quantifying impact of changes

Slide 17 Impact of high lapses Impact of higher lapses on claims experience e.g. move from 4yr to 2yr commission Assume excess lapses are ‘healthy’ lives – i.e. wouldn’t be rated at time of lapse. These lives would therefore have better claim experience that the remainder of the cohort Judgement required on how much healthier!!

Slide 18 Agenda Experience analysis – a brief overview Finding a plausible answer Risk selection CI related issues Changing HIV limits Impact of high lapses Quantifying impact of changes

Slide 19 Quantifying impact of changes Business operations constantly changing, e.g. intro of tele u/w, more leniency on non- disclosure, changes to proposal form => impacts claims experience How could claims experience be “corrected” for these changes? Might be possible to rate changes and track over time Ratings subjective at first, but over time possible to develop feel for how changes might impact claims experience enabling cost/benefit analyses Quality of proposal form U/W philosophyInternal controls Electronic acceptance Non disclosureTele u/wTotal U/W “score” xx yy Claims Philosophy Ratio of staff to claims Quality of evidence gathering Experience of staff Audit findingsMedical limitsTotal Claims “score” xx yy

Slide 20 Key take-aways Understand the data – not all fluctuations are random What’s changed or changing? – Talk to marketing, underwriting, claims, risk management, distributors, customers Adjust historic data to make it relevant for projecting the future – Correct for distortions in experience data – Bring together different data sources New realistic reporting and solvency environment – Important to justify assumptions

Slide 21 Questions